missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ Human LRRK2 (aa 1518-1653) Control Fragment Recombinant Protein
Click to view available options
Quantity:
100 μL
Packungsgröße:
100µL
Beschreibung
Highest antigen sequence indentity to the following orthologs: Mouse (91%), Rat (91%). This recombinant protein control fragment may be used for blocking experiments. In IHC/ICC and WB experiments, we recommend a 100x molar excess of the protein fragment control based on the concentration and the molecular weight. Pre-incubate the antibody-protein control fragment mixture for 30 min at room temperature.
LRRK2 is a multidomain protein that includes a kinase domain, a GTPase domain, and a leucine-rich repeat (LRR) domain. Mutations in LRRK2 have been associated with Parkinson's disease. LRRK2 is a member of the leucine-rich repeat kinase family and encodes a protein with an ankryin repeat region, a leucine-rich repeat domain, a kinase domain, a DFG-like motif, a RAS domain, a GTPase domain, a MLK-like domain, and a WD40 domain. The protein is present largely in the cytoplasm but also associates with the mitochondrial outer membrane.
Spezifikation
Spezifikation
| Accession Number | Q5S007 |
| Concentration | ≥5.0 mg/mL |
| For Use With (Application) | Blocking Assay, Control |
| Formulation | 1 M urea, PBS with no preservative; pH 7.4 |
| Gene ID (Entrez) | 120892 |
| Name | Human LRRK2 (aa 1518-1653) Control Fragment |
| Quantity | 100 μL |
| Regulatory Status | RUO |
| Gene Alias | 4921513O20Rik; 9330188B09Rik; augmented in rheumatoid arthritis 17; AURA17; AW561911; BC 300-268; cI-46; D630001M17Rik; DARDARIN; DKFZp434H2111; FLJ45829; Gm927; leucine rich repeat kinase 2; leucine-rich repeat kinase 2; leucine-rich repeat serine/threonine-protein kinase 2; LRR kinase 2; LRRK 2; Lrrk2; LRRK-2; PARK8; RIPK7; ROCO2 |
| Common Name | LRRK2 |
| Mehr anzeigen |
Berichtigung von Produktinhalten
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.
Name des Produkts
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur